Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of sofosbuvir/velpatasvir/GS-9857 in DAA-experienced chronic HCV
2015-003455-21Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sofosbuvir, velpatasvir and voxilaprevir in chronic hepatitis C (CHC) (2 arms), sponsored by Gilead Sciences. Primary endpoint: SVR12 in Group 1 (primary efficacy endpoint). Started Oct 2015; status: completed.
02
Drugs
sofosbuvirvelpatasvirvoxilaprevir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2015-003455-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003455-21.